Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.

Maurillo L, Bassan R, Cascavilla N, Ciceri F.

Cancers (Basel). 2019 Sep 23;11(10). pii: E1417. doi: 10.3390/cancers11101417. Review.

2.

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.

Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R.

Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170. [Epub ahead of print]

PMID:
31298059
3.

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges.

Soverini S, Bassan R, Lion T.

J Hematol Oncol. 2019 Apr 23;12(1):39. doi: 10.1186/s13045-019-0729-2. Review.

4.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.

Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Ciceri F, Bernardi M, Scattolin AM, Todisco E, Campiotti L, Corradini P, Cortelezzi A, Ferrero D, Zanghì P, Oldani E, Spinelli O, Audisio E, Cortelazzo S, Bosi A, Falini B, Pogliani EM, Rambaldi A.

Blood Adv. 2019 Apr 9;3(7):1103-1117. doi: 10.1182/bloodadvances.2018026625.

5.

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.

Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S.

Haematologica. 2019 Oct;104(10):2028-2039. doi: 10.3324/haematol.2018.201053. Epub 2019 Mar 19.

6.

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study.

Bassan R, Hoelzer D, Thomas X, Montesinos P, Pavlu J, McKendrick J, Kudlac A, Barlev A, Barber B, Cong Z.

Adv Ther. 2019 Apr;36(4):870-879. doi: 10.1007/s12325-019-00910-z. Epub 2019 Mar 7.

7.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.

Hematology. 2019 Dec;24(1):337-348. doi: 10.1080/16078454.2019.1567654.

8.

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.

Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S.

J Clin Oncol. 2018 Sep 21:JCO2017773648. doi: 10.1200/JCO.2017.77.3648. [Epub ahead of print]

PMID:
30240326
9.

Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.

Bassan R, Intermesoli T, Scattolin A, Viero P, Maino E, Sancetta R, Carobolante F, Gianni F, Stefanoni P, Tosi M, Spinelli O, Rambaldi A.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S2-S9. doi: 10.1016/j.clml.2017.02.019. Review.

PMID:
28760298
10.

Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia.

Bassan R.

Lancet Haematol. 2017 Aug;4(8):e346-e347. doi: 10.1016/S2352-3026(17)30121-7. Epub 2017 Jul 4. No abstract available.

PMID:
28687419
11.

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.

Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Review.

PMID:
28506131
12.

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.

Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AM, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A.

Haematologica. 2017 Mar;102(3):529-540. doi: 10.3324/haematol.2016.151910. Epub 2016 Nov 10.

13.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

14.

Burkitt lymphoma in adolescents and young adults: management challenges.

Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R.

Adolesc Health Med Ther. 2016 Dec 23;8:11-29. doi: 10.2147/AHMT.S94170. eCollection 2017. Review.

15.

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H.

Blood Cancer J. 2016 Sep 23;6(9):e473. doi: 10.1038/bcj.2016.84.

16.

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H.

Haematologica. 2016 Dec;101(12):1524-1533. Epub 2016 Sep 1.

17.

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.

Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, Oldani E, Tosi M, Grassi A, Parolini M, Audisio E, Cattaneo C, Raimondi R, Angelucci E, Cavattoni IM, Scattolin AM, Cortelezzi A, Mannelli F, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Romani C, Bassan R, Rambaldi A.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1983-1987. doi: 10.1016/j.bbmt.2016.07.021. Epub 2016 Aug 1.

18.

Reply to C.S. Hourigan et al.

Bassan R.

J Clin Oncol. 2016 Jul 20;34(21):2559-60. doi: 10.1200/JCO.2016.67.6700. Epub 2016 May 16. No abstract available.

PMID:
27185844
19.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group.

Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27.

20.

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v69-v82. Epub 2016 Apr 7. No abstract available.

PMID:
27056999
21.

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

Maino E, Bonifacio M, Scattolin AM, Bassan R.

Expert Rev Hematol. 2016 Jun;9(6):563-77. doi: 10.1586/17474086.2016.1170593. Epub 2016 Apr 8. Review.

PMID:
27011303
22.

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Salmoiraghi S, Montalvo ML, Ubiali G, Tosi M, Peruta B, Zanghi P, Oldani E, Boschini C, Kohlmann A, Bungaro S, Intermesoli T, Terruzzi E, Angelucci E, Cavattoni I, Ciceri F, Bassan R, Rambaldi A, Spinelli O.

Haematologica. 2016 Jun;101(6):e245-8. doi: 10.3324/haematol.2015.137059. Epub 2016 Mar 18. No abstract available.

23.

Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome.

Bassan F, Bassan R, Esporcatte R, Santos B, Tura B.

Arq Bras Cardiol. 2016 Mar;106(3):218-25. doi: 10.5935/abc.20160021. Epub 2016 Feb 2. English, Portuguese.

24.

Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment.

Bassan R, Maino E, Cortelazzo S.

Eur J Haematol. 2016 May;96(5):447-60. doi: 10.1111/ejh.12722. Epub 2016 Jan 24. Review.

PMID:
26679753
25.

Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia.

Bassan R.

J Clin Oncol. 2016 Feb 1;34(4):300-2. doi: 10.1200/JCO.2015.64.8907. Epub 2015 Dec 14. No abstract available.

PMID:
26668347
26.

[V Guideline of the Brazilian Society of Cardiology on Acute Myocardial Infarction Treatment with ST Segment Elevation].

Avezum Junior Á, Feldman A, Carvalho AC, Sousa AC, Mansur Ade P, Bozza AE, Falcão Bde A, Markman Filho BM, Polanczyk CA, Gun C, Serrano Junior CV, Oliveira CC, Moreira D, Précoma DB, Magnoni D, Albuquerque DC, Romano ER, Stefanini E, Santos ES, God EM, Ribeiro EE, Brito FS, Feitosa-Filho GS, Arruda GD, Oliveira GB, Lima GG, Dohman H, Liguori IM, Costa Junior Jde R, Saraiva JF, Maia LN, Moreira LF, Santos MA, Canesin MF, Coutinho MS, Moretti AM, Ghorayeb N, Vieira NW, Dutra OP, Coelho OR, Leães PE, Rossi PR, Andrade PB, Lemos Neto PA, Pavanello R, Costa RV, Bassan R, Esporcatte R, Miranda R, Giraldez RR, Ramos RF, Martins SK, Esteves VB, Mathias Junior W; Brazilian Society of Cardiology.

Arq Bras Cardiol. 2015 Aug;105(2 Suppl 1):1-105. doi: 10.5935/abc.20150107. Portuguese. No abstract available.

27.

Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.

Bassan R, Spinelli O.

Curr Hematol Malig Rep. 2015 Jun;10(2):86-95. doi: 10.1007/s11899-015-0252-7. Review.

PMID:
25929769
28.

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.

Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A.

Haematologica. 2015 Jun;100(6):786-93. doi: 10.3324/haematol.2014.123273. Epub 2015 Mar 6.

29.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.

PMID:
25585678
30.

Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.

Maino E, Scattolin AM, Viero P, Sancetta R, Pascarella A, Vespignani M, Bassan R.

Mediterr J Hematol Infect Dis. 2015 Jan 1;7(1):e2015001. doi: 10.4084/MJHID.2015.001. eCollection 2015. Review.

31.

Diagnosis and subclassification of acute lymphoblastic leukemia.

Chiaretti S, Zini G, Bassan R.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014073. doi: 10.4084/MJHID.2014.073. eCollection 2014. Review.

32.

Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia.

Spinelli O, Tosi M, Peruta B, Guinea Montalvo ML, Maino E, Scattolin AM, Parolini M, Viero P, Rambaldi A, Bassan R.

Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014062. doi: 10.4084/MJHID.2014.062. eCollection 2014. Review.

33.

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.

Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Björkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, Lister A.

Br J Haematol. 2014 Dec;167(5):724-6. doi: 10.1111/bjh.13055. Epub 2014 Jul 29. No abstract available.

PMID:
25074579
34.

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A.

Blood Cancer J. 2014 Jul 11;4:e225. doi: 10.1038/bcj.2014.48. No abstract available.

35.

Current and future management of Ph/BCR-ABL positive ALL.

Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, Bassan R.

Expert Rev Anticancer Ther. 2014 Jun;14(6):723-40. doi: 10.1586/14737140.2014.895669. Epub 2014 Mar 10. Review.

PMID:
24611626
36.

Ph+ ALL: imatinib grows older with patients.

Bassan R.

Blood. 2014 Feb 6;123(6):801-3. doi: 10.1182/blood-2013-12-542423. No abstract available.

PMID:
24505064
37.

Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient.

Parolini M, Mecucci C, Matteucci C, Giussani U, Intermesoli T, Tosi M, Rambaldi A, Bassan R.

Blood Cancer J. 2014 Jan 17;4:e176. doi: 10.1038/bcj.2013.72. No abstract available.

38.

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.

Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R.

Haematologica. 2013 Nov;98(11):1718-25. doi: 10.3324/haematol.2013.086827. Epub 2013 Jun 10.

39.

Toward victory in adult ALL: blinatumomab joins in.

Bassan R.

Blood. 2012 Dec 20;120(26):5094-5. doi: 10.1182/blood-2012-10-460394. No abstract available.

PMID:
23258898
40.

Modern therapy of young and adult Ph-ALL.

Bassan R, Intermesoli T, Spinelli O, Oldani E, Rambaldi A.

Leuk Suppl. 2012 Aug;1(Suppl 2):S5-6. doi: 10.1038/leusup.2012.6. Epub 2012 Aug 9.

41.

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.

Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, Romani C, Ciceri F, Corti C, Scattolin A, Cortelezzi A, Mattei D, Audisio E, Spinelli O, Oldani E, Bosi A, Rambaldi A, Bassan R.

Haematologica. 2012 Apr;97(4):568-71. doi: 10.3324/haematol.2011.054064. Epub 2011 Nov 4.

42.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, Pasqualucci L, Rabadan R, Haferlach T, Falini B.

Blood. 2011 Dec 1;118(23):6153-63. doi: 10.1182/blood-2011-07-365320. Epub 2011 Oct 19.

PMID:
22012066
43.

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

Intermesoli T, Castagnetti F, Soverini S, Bussini A, Spinelli O, Gnani A, Bassan R, Rosti G.

Leuk Res. 2012 Jan;36(1):e10-1. doi: 10.1016/j.leukres.2011.09.002. Epub 2011 Oct 1. No abstract available.

PMID:
21962337
44.

Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?

Bassan R.

Leuk Lymphoma. 2011 Jul;52(7):1164-5. doi: 10.3109/10428194.2011.575494. Epub 2011 May 25. No abstract available.

PMID:
21612380
45.

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma.

Cortelazzo S, Intermesoli T, Oldani E, Ciceri F, Rossi G, Pogliani EM, Mattei D, Romani C, Cortelezzi A, Borlenghi E, Corti C, Peruta B, Spinelli O, Rambaldi A, Bassan R.

Ann Hematol. 2012 Jan;91(1):73-82. doi: 10.1007/s00277-011-1252-x. Epub 2011 May 11.

46.

Modern therapy of acute lymphoblastic leukemia.

Bassan R, Hoelzer D.

J Clin Oncol. 2011 Feb 10;29(5):532-43. doi: 10.1200/JCO.2010.30.1382. Epub 2011 Jan 10. Review.

PMID:
21220592
47.

The European LeukemiaNet: achievements and perspectives.

Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet.

Haematologica. 2011 Jan;96(1):156-62. doi: 10.3324/haematol.2010.032979. Epub 2010 Nov 3.

48.

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Gökbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernández-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D; German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL.

Haematologica. 2011 Feb;96(2):238-44. doi: 10.3324/haematol.2010.028092. Epub 2010 Oct 15.

49.

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A.

J Clin Oncol. 2010 Aug 1;28(22):3644-52. doi: 10.1200/JCO.2010.28.1287. Epub 2010 Jul 6.

PMID:
20606084
50.

Persistent aryl hydrocarbon receptor inducers increase with altitude, and estrogen-like disrupters are low in soils of the Alps.

Levy W, Henkelmann B, Bernhöft S, Bovee T, Buegger F, Jakobi G, Kirchner M, Bassan R, Kräuchi N, Moche W, Offenthaler I, Simončič P, Weiss P, Schramm KW.

Environ Sci Pollut Res Int. 2011 Jan;18(1):99-110. doi: 10.1007/s11356-010-0361-8. Epub 2010 Jun 24. Erratum in: Environ Sci Pollut Res Int. 2015 Feb;22(4):3180-1.

PMID:
20574780

Supplemental Content

Loading ...
Support Center